The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in the Asia Pacific is estimated to value USD 625.94 million by 2027 from USD 427.99 million in 2022, projecting a CAGR of 7.9% from 2022 to 2027.
The rising prevalence of acute ischemic stroke cases, technological advancements in surgical procedures, aging population, and growth in healthcare spending are expected to drive the APAC Acute Ischemic stroke diagnostic and treatment market during the forecast period. In addition, a large population base and a rising incidence of cardiovascular disease are other important factors driving the market expansion.
Rising tobacco consumption and diabetes incidences in an aging population are critical factors influencing the market growth. Furthermore, the market is expanding due to an increase in the number of surgical operations used to treat strokes as the number of cases of cerebral ischemia rises. Growing healthcare spending, advanced surgical techniques, and the growing demand for more minor invasive procedures are the major factors driving the acute ischemic stroke diagnostic and treatment market.
One of the other primary market drivers is the expanding geriatric population in developed and emerging nations, as older people are more susceptible to stroke than younger populations. Furthermore, the increased demand for less invasive methods and the increased effect of telemedicine, e-prescription, and e-medical are projected to be important factors driving the growth of the acute ischemic stroke diagnosis and treatment market. The APAC region's acute ischemic stroke diagnosis and treatment market are further predicted to grow significantly due to the increased awareness of stroke and accessible treatment choices in the market, positive government initiatives, and quick technical advancements.
Some of the factors restricting the market expansion are the excessive use of medicines to treat ischemic stroke and the high cost of surgical treatments. In addition, the many complications associated with product development and production may impede the acute ischemic stroke diagnosis and treatment market growth in the APAC region.
This research report on the APAC Acute Ischemic Stroke Treatment & Diagnosis Market is segmented and sub-segmented into the following categories:
By Diagnostic Type:
By Surgery Type:
The APAC is one of the fastest-growing regions globally in the Acute Ischemic stroke diagnostic and treatment market. The market growth is attributed to the rising number of ischemic stroke patients in the region. In addition, the manufacturers are extending their operations which offers significant market growth potential in the Asia Pacific region, which has enormous market growth potential. Because it has emerged as the most potential market for ischemic stroke diagnosis and treatment, the region sees a surge in the prevalence of strokes. Moreover, the leading contributors of acute ischemic stroke diagnosis goods are growing their market in Asian countries like India, China, Japan, and South Korea, where acute ischemic stroke diagnosis and treatment products have enormous potential.
China and India are expected to be the fastest-growing markets in the acute ischemic stroke diagnosis and treatment industry in the coming years. The China acute ischemic stroke diagnosis and treatment market is expected to grow at the fastest rate. Favourable government initiatives and improvements in healthcare infrastructure, which are expected to propel market growth.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the APAC acute ischemic stroke treatment & diagnosis market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org